{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:06:44Z","timestamp":1777529204715,"version":"3.51.4"},"reference-count":47,"publisher":"Wiley","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["L3-3648"],"award-info":[{"award-number":["L3-3648"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["P1-0170"],"award-info":[{"award-number":["P1-0170"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["L3-3648"],"award-info":[{"award-number":["L3-3648"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Javna Agencija za Raziskovalno Dejavnost RS","doi-asserted-by":"publisher","award":["P1-0170"],"award-info":[{"award-number":["P1-0170"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Disease Markers"],"published-print":{"date-parts":[[2015]]},"abstract":"<jats:p><jats:italic>Background.<\/jats:italic>Survivin is an inhibitor of apoptosis protein involved in the regulation of cell proliferation that could be used as a marker for cancer diagnosis or prognosis. Our aim was to evaluate whether serum survivin levels influence the outcome of cisplatin-based chemotherapy in patients with malignant mesothelioma (MM).<jats:italic>Methods.<\/jats:italic>Serum survivin levels were determined using human survivin enzyme-linked immunosorbent assay in 78 MM patients before chemotherapy, after chemotherapy, and at disease progression. The influence on tumor response and survival was evaluated using nonparametric tests and Cox regression.<jats:italic>Results.<\/jats:italic>A median serum survivin level at diagnosis was 4.1 (0\u2013217.5)\u2009pg\/mL. Patients with a progressive disease had significantly higher survivin levels before chemotherapy (<jats:italic>p<\/jats:italic>= 0.041). A median serum survivin level after chemotherapy was 73.1 (0\u2013346.2)\u2009pg\/mL. If survivin levels increased after chemotherapy, patients had, conversely, better response (<jats:italic>p<\/jats:italic>= 0.001, OR = 5.40, 95% CI = 1.98\u201314.72). Unexpectedly, patients with increased survivin levels after chemotherapy also had longer progression-free (<jats:italic>p<\/jats:italic>&lt; 0.001, HR = 0.33, 95% CI = 0.20\u20130.57) and overall survival (<jats:italic>p<\/jats:italic>= 0.001, HR = 0.29, 95% CI = 0.14\u20130.58).<jats:italic>Conclusions.<\/jats:italic>These results suggest that serum survivin levels before and during chemotherapy could serve as a biomarker predicting MM treatment response.<\/jats:p>","DOI":"10.1155\/2015\/316739","type":"journal-article","created":{"date-parts":[[2015,9,16]],"date-time":"2015-09-16T17:02:56Z","timestamp":1442422976000},"page":"1-8","source":"Crossref","is-referenced-by-count":11,"title":["Serum Survivin Levels and Outcome of Chemotherapy in Patients with Malignant Mesothelioma"],"prefix":"10.1155","volume":"2015","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5673-4458","authenticated-orcid":true,"given":"Katja","family":"Gori\u010dar","sequence":"first","affiliation":[{"name":"Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, SI-1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viljem","family":"Kova\u010d","sequence":"additional","affiliation":[{"name":"Institute of Oncology Ljubljana, SI-1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alenka","family":"Franko","sequence":"additional","affiliation":[{"name":"Clinical Institute of Occupational Medicine, University Medical Center Ljubljana, SI-1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3845-4804","authenticated-orcid":true,"given":"Metoda","family":"Dodi\u010d-Fikfak","sequence":"additional","affiliation":[{"name":"Clinical Institute of Occupational Medicine, University Medical Center Ljubljana, SI-1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vita","family":"Dol\u017ean","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Laboratory, Institute of Biochemistry, Faculty of Medicine, University of Ljubljana, SI-1000 Ljubljana, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-08-0746"},{"key":"2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-04-1918"},{"key":"3","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2007.06.004"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2009.05.003"},{"key":"5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-07-0494"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2004.04.002"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2007.08.005"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-07-0109"},{"issue":"22","key":"9","first-page":"5071","volume":"58","year":"1998","journal-title":"Cancer Research"},{"issue":"7","key":"10","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1200\/JCO.1999.17.7.2100","volume":"17","year":"1999","journal-title":"Journal of Clinical Oncology"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2990.2005.00664.x"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.1136\/gut.46.5.645"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-004-2353-3"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28200"},{"key":"15","doi-asserted-by":"publisher","DOI":"10.1016\/s1368-7646(02)00049-3"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.2478\/v10019-012-0032-0"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00153611"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0b013e32834d7a1c"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2008.09.008"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.2478\/raon-2013-0086"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1097\/jto.0b013e318275b346"},{"key":"23","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-011-1030-0"},{"key":"24","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-013-1373-9"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2004.10.003"},{"key":"26","doi-asserted-by":"publisher","DOI":"10.1002\/path.2121"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2006.12.013"},{"issue":"6","key":"28","first-page":"453","volume":"29","year":"2007","journal-title":"Cellular Oncology"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.3233\/dma-2011-0866"},{"key":"30","doi-asserted-by":"publisher","DOI":"10.1515\/raon-2015-0019"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnci.2011.12.006"},{"key":"32","doi-asserted-by":"publisher","DOI":"10.1385\/mo:23:3:335"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1684\/ecn.2013.0340"},{"key":"34","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0167-5"},{"issue":"20","key":"35","first-page":"3063","volume":"18","year":"2014","journal-title":"European Review for Medical and Pharmacological Sciences"},{"key":"36","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh059"},{"key":"37","first-page":"122","volume-title":"Survivin expression in response to cisplatin-induced stress","year":"2013"},{"key":"38","doi-asserted-by":"publisher","DOI":"10.2478\/v10042-009-0025-z"},{"key":"39","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22380"},{"key":"40","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600776"},{"key":"41","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-005-0682-z"},{"key":"42","doi-asserted-by":"publisher","DOI":"10.1053\/ejso.2002.1415"},{"key":"43","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh436"},{"key":"44","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2011.06.037"},{"key":"45","doi-asserted-by":"publisher","DOI":"10.1159\/000432398"},{"key":"46","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-005-9153-0"},{"key":"47","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.3050"}],"container-title":["Disease Markers"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/dm\/2015\/316739.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/dm\/2015\/316739.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/dm\/2015\/316739.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T15:41:45Z","timestamp":1498232505000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.hindawi.com\/journals\/dm\/2015\/316739\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":47,"alternative-id":["316739","316739"],"URL":"https:\/\/doi.org\/10.1155\/2015\/316739","relation":{},"ISSN":["0278-0240","1875-8630"],"issn-type":[{"value":"0278-0240","type":"print"},{"value":"1875-8630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}